tazobactam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-lactamase inhibitors 2572 89786-04-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tazobactam
  • tazobactam sodium
  • YTR-830
  • YTR 830
A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.
  • Molecular weight: 300.29
  • Formula: C10H12N4O5S
  • CLOGP: -0.65
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 122.46
  • ALOGS: -1.50
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 77 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 66.49 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.26 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.81 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.97 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 18, 2015 EMA MERCK SHARP & DOHME B.V.
Oct. 22, 1993 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 111.06 19.03 117 8213 151040 63329652
Sepsis 92.51 19.03 107 8223 153016 63327676
Acute kidney injury 72.06 19.03 126 8204 263289 63217403
Respiratory failure 67.96 19.03 75 8255 101783 63378909
Pyrexia 67.77 19.03 173 8157 470305 63010387
Multiple organ dysfunction syndrome 62.56 19.03 55 8275 56697 63423995
Renal failure 60.80 19.03 76 8254 117576 63363116
Pancytopenia 58.90 19.03 68 8262 96865 63383827
Eosinophilia 56.68 19.03 36 8294 22720 63457972
Leukopenia 55.18 19.03 59 8271 77231 63403461
Dermatitis exfoliative generalised 50.65 19.03 19 8311 3788 63476904
Disseminated intravascular coagulation 49.60 19.03 31 8299 19020 63461672
Toxic epidermal necrolysis 48.44 19.03 34 8296 25300 63455392
Septic shock 47.80 19.03 51 8279 66578 63414114
Rash maculo-papular 43.58 19.03 35 8295 31861 63448831
Platelet count decreased 41.80 19.03 63 8267 116059 63364633
Arthralgia 39.24 19.03 13 8317 569697 62910995
Rash morbilliform 38.51 19.03 15 8315 3310 63477382
Haemoglobin decreased 37.62 19.03 68 8262 145417 63335275
Tubulointerstitial nephritis 36.40 19.03 26 8304 19877 63460815
Pleural effusion 35.59 19.03 52 8278 93158 63387534
Nephropathy toxic 34.06 19.03 19 8311 9460 63471232
Drug reaction with eosinophilia and systemic symptoms 33.73 19.03 31 8299 33805 63446887
Blood creatinine increased 33.53 19.03 49 8281 87795 63392897
Febrile neutropenia 32.72 19.03 57 8273 118392 63362300
Drug ineffective 32.26 19.03 55 8275 1044710 62435982
Pseudomonal sepsis 32.00 19.03 12 8318 2389 63478303
Heparin-induced thrombocytopenia 30.68 19.03 14 8316 4568 63476124
Fatigue 29.98 19.03 44 8286 887984 62592708
Drug intolerance 29.77 19.03 3 8327 308658 63172034
Joint swelling 29.58 19.03 4 8326 327662 63153030
Agranulocytosis 28.97 19.03 25 8305 25109 63455583
Toxic skin eruption 28.68 19.03 19 8311 12866 63467826
Prothrombin time prolonged 28.58 19.03 17 8313 9547 63471145
Platelet count increased 27.57 19.03 21 8309 17690 63463002
Abdominal discomfort 26.53 19.03 5 8325 320880 63159812
Alopecia 26.38 19.03 6 8324 337530 63143162
Acute generalised exanthematous pustulosis 26.25 19.03 17 8313 11082 63469610
Linear IgA disease 25.90 19.03 9 8321 1442 63479250
White blood cell count decreased 25.12 19.03 56 8274 139048 63341644
Headache 24.81 19.03 28 8302 633213 62847479
Neutropenia 24.67 19.03 64 8266 174941 63305751
Leukocytosis 24.38 19.03 23 8307 25912 63454780
Anaemia 23.40 19.03 88 8242 293342 63187350
Stevens-Johnson syndrome 23.21 19.03 22 8308 24928 63455764
Aspergillus infection 23.18 19.03 14 8316 8079 63472613
Dizziness 23.01 19.03 14 8316 429911 63050781
Haemolytic anaemia 22.70 19.03 15 8315 10110 63470582
Brain oedema 22.47 19.03 17 8313 14178 63466514
Cytomegalovirus infection 22.46 19.03 20 8310 20932 63459760
Fall 22.10 19.03 12 8318 392322 63088370
Acinetobacter infection 21.42 19.03 8 8322 1575 63479117
Hypokalaemia 21.27 19.03 44 8286 103760 63376932
Product contamination microbial 20.83 19.03 5 8325 214 63480478
Acute respiratory distress syndrome 20.47 19.03 20 8310 23514 63457178
Hypotension 19.48 19.03 79 8251 272525 63208167
Cytarabine syndrome 19.36 19.03 4 8326 85 63480607
Unresponsive to stimuli 19.31 19.03 23 8307 33793 63446899
Pseudomembranous colitis 19.25 19.03 9 8321 3103 63477589
Streptococcal infection 19.17 19.03 11 8319 5776 63474916
Clostridial infection 19.12 19.03 10 8320 4382 63476310

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lymphocyte count abnormal 113.74 16 33 11401 1165 34944332
Tubulointerstitial nephritis 90.29 16 66 11368 20958 34924539
Acute kidney injury 87.06 16 257 11177 304731 34640766
Thrombocytopenia 84.84 16 169 11265 156078 34789419
Sepsis 72.86 16 165 11269 166396 34779101
Pyrexia 71.78 16 255 11179 332758 34612739
Platelet count decreased 64.31 16 129 11305 119588 34825909
Neutrophil count increased 62.90 16 49 11385 17097 34928400
Choroiditis 58.78 16 20 11414 1195 34944302
Neutropenia 56.34 16 144 11290 156634 34788863
Delusion of grandeur 55.75 16 19 11415 1141 34944356
Multiple organ dysfunction syndrome 51.65 16 91 11343 76475 34869022
Clostridial infection 46.39 16 23 11411 3604 34941893
Rhinalgia 45.77 16 16 11418 1037 34944460
Disseminated intravascular coagulation 43.23 16 44 11390 21772 34923725
Cholestasis 42.23 16 48 11386 26900 34918597
Leukopenia 41.46 16 74 11360 62782 34882715
Dizziness 40.05 16 11 11423 218510 34726987
Renal tubular necrosis 39.32 16 36 11398 15644 34929853
Septic shock 39.22 16 78 11356 71756 34873741
Agranulocytosis 38.30 16 43 11391 23778 34921719
Rash 38.27 16 159 11275 222593 34722904
Stevens-Johnson syndrome 37.68 16 38 11396 18601 34926896
Drug reaction with eosinophilia and systemic symptoms 37.50 16 50 11384 32962 34912535
Respiratory failure 35.14 16 96 11338 108476 34837021
Intraocular pressure increased 32.83 16 21 11413 5362 34940135
Heparin-induced thrombocytopenia 32.09 16 21 11413 5574 34939923
Nephropathy toxic 31.76 16 29 11405 12559 34932938
Affective disorder 31.64 16 19 11415 4341 34941156
Congenital pneumonia 30.46 16 7 11427 95 34945402
Clostridium difficile colitis 29.85 16 31 11403 15699 34929798
Renal failure 29.67 16 102 11332 130455 34815042
Eosinophilia 28.68 16 39 11395 26183 34919314
Blood creatinine increased 27.80 16 81 11353 94895 34850602
Uveitis 26.47 16 21 11413 7514 34937983
Lymphocyte count 25.93 16 6 11428 84 34945413
Death 25.53 16 58 11376 397991 34547506
Chills 24.56 16 70 11364 80973 34864524
Headache 24.44 16 18 11416 200617 34744880
Pneumonia staphylococcal 24.10 16 14 11420 3010 34942487
Alanine aminotransferase increased 23.72 16 69 11365 80746 34864751
Subclavian artery occlusion 23.70 16 6 11428 125 34945372
Spontaneous haematoma 22.80 16 8 11426 524 34944973
Transplant rejection 22.65 16 22 11412 10289 34935208
Haemodialysis 22.26 16 22 11412 10504 34934993
Hepatic failure 21.91 16 40 11394 34491 34911006
Acute respiratory distress syndrome 21.68 16 34 11400 25935 34919562
Autoimmune haemolytic anaemia 21.31 16 15 11419 4481 34941016
Rash erythematous 21.27 16 33 11401 24944 34920553
Eye pain 21.12 16 24 11410 13438 34932059
Dialysis 21.10 16 22 11412 11186 34934311
Arthralgia 21.03 16 15 11419 170026 34775471
Blood alkaline phosphatase increased 20.92 16 37 11397 31138 34914359
Lymphocyte count decreased 20.83 16 31 11403 22591 34922906
Pancytopenia 20.43 16 73 11361 95084 34850413
Organ failure 20.24 16 11 11423 2080 34943417
Gamma-glutamyltransferase increased 20.01 16 35 11399 29196 34916301
Aspartate aminotransferase increased 20.00 16 58 11376 67725 34877772
Schizophrenia 20.00 16 19 11415 8647 34936850
Respiratory distress 19.77 16 39 11395 35626 34909871
SARS-CoV-2 test positive 19.70 16 16 11418 5917 34939580
Rash maculo-papular 19.39 16 34 11400 28417 34917080
Drug eruption 19.38 16 28 11406 19870 34925627
Hepatic function abnormal 19.36 16 44 11390 44319 34901178
Dermatitis exfoliative 18.13 16 16 11418 6623 34938874
Blood bilirubin increased 17.85 16 39 11395 38257 34907240
Hepatocellular injury 17.06 16 28 11406 22183 34923314
Hepatic cytolysis 16.52 16 22 11412 14474 34931023
Weight increased 16.43 16 5 11429 93028 34852469
Anaphylactic reaction 16.33 16 34 11400 32267 34913230
Scar pain 16.15 16 4 11430 76 34945421
Visual acuity reduced 16.13 16 23 11411 16126 34929371
Nephritis 16.04 16 10 11424 2441 34943056

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 152.83 16.65 332 16071 519072 79208913
Thrombocytopenia 144.96 16.65 222 16181 265037 79462948
Sepsis 124.57 16.65 209 16194 269219 79458766
Tubulointerstitial nephritis 115.93 16.65 81 16322 38154 79689831
Pyrexia 96.36 16.65 332 16071 678377 79049608
Renal failure 85.03 16.65 150 16253 200818 79527167
Septic shock 84.82 16.65 115 16288 122686 79605299
Multiple organ dysfunction syndrome 83.64 16.65 113 16290 120133 79607852
Eosinophilia 80.53 16.65 70 16333 45275 79682710
Leukopenia 77.27 16.65 107 16296 116406 79611579
Platelet count decreased 71.85 16.65 137 16266 194527 79533458
Drug reaction with eosinophilia and systemic symptoms 70.29 16.65 76 16327 64168 79663817
Neutropenia 66.83 16.65 168 16235 287542 79440443
Choroiditis 65.38 16.65 20 16383 1361 79726624
Clostridial infection 61.98 16.65 28 16375 5686 79722299
Respiratory failure 61.49 16.65 123 16280 180788 79547197
Nephropathy toxic 61.27 16.65 43 16360 20376 79707609
Arthralgia 60.72 16.65 21 16382 571782 79156203
Delusion of grandeur 60.47 16.65 19 16384 1413 79726572
Dizziness 60.07 16.65 17 16386 526424 79201561
Rash maculo-papular 59.01 16.65 65 16338 56013 79671972
Disseminated intravascular coagulation 57.02 16.65 52 16351 35790 79692195
Heparin-induced thrombocytopenia 56.12 16.65 31 16372 9651 79718334
Agranulocytosis 55.91 16.65 57 16346 44973 79683012
Pancytopenia 54.30 16.65 111 16292 165634 79562351
Stevens-Johnson syndrome 51.23 16.65 51 16352 39115 79688870
Headache 50.02 16.65 37 16366 653735 79074250
Transplant rejection 47.15 16.65 36 16367 19401 79708584
Renal tubular necrosis 45.14 16.65 39 16364 25000 79702985
Joint swelling 44.68 16.65 4 16399 288642 79439343
Fatigue 43.68 16.65 78 16325 929649 78798336
Cholestasis 40.89 16.65 52 16351 52057 79675928
Toxic epidermal necrolysis 40.67 16.65 48 16355 44533 79683452
Rhinalgia 40.37 16.65 16 16387 2351 79725634
Clostridium difficile colitis 40.31 16.65 41 16362 32242 79695743
Blood creatinine increased 38.53 16.65 93 16310 154964 79573021
Dialysis 37.91 16.65 31 16372 18431 79709554
Acute generalised exanthematous pustulosis 37.61 16.65 30 16373 17224 79710761
Nasopharyngitis 35.56 16.65 5 16398 253876 79474109
Weight increased 35.45 16.65 7 16396 277379 79450606
Drug intolerance 35.18 16.65 6 16397 264113 79463872
Acute respiratory distress syndrome 34.62 16.65 44 16359 44023 79683962
Autoimmune haemolytic anaemia 33.24 16.65 21 16382 8359 79719626
Fall 33.05 16.65 31 16372 487598 79240387
Toxic skin eruption 32.85 16.65 31 16372 22262 79705723
Neutrophil count increased 32.53 16.65 35 16368 29361 79698624
Lymphocyte count abnormal 32.22 16.65 12 16391 1491 79726494
Rash 32.09 16.65 216 16187 578142 79149843
Prothrombin time prolonged 31.84 16.65 27 16376 16872 79711113
Intraocular pressure increased 31.43 16.65 21 16382 9184 79718801
Dermatitis exfoliative generalised 30.87 16.65 19 16384 7222 79720763
Febrile neutropenia 29.97 16.65 110 16293 230889 79497096
Hypotension 29.74 16.65 173 16230 440144 79287841
Abdominal discomfort 28.72 16.65 8 16395 250719 79477266
Neutrophil count decreased 28.49 16.65 61 16342 93898 79634087
Affective disorder 28.46 16.65 19 16384 8300 79719685
Haemodialysis 28.19 16.65 26 16377 18142 79709843
Respiratory distress 27.85 16.65 46 16357 58293 79669692
Renal impairment 27.47 16.65 83 16320 157700 79570285
Haemoglobin decreased 27.34 16.65 104 16299 222015 79505970
Linear IgA disease 26.71 16.65 13 16390 3119 79724866
Immune effector cell-associated neurotoxicity syndrome 26.62 16.65 16 16387 5832 79722153
Weight decreased 25.96 16.65 21 16382 355177 79372808
Rash morbilliform 25.87 16.65 16 16387 6134 79721851
Nephritis 25.82 16.65 14 16389 4200 79723785
Enterococcal infection 25.45 16.65 23 16380 15637 79712348
Acinetobacter infection 25.11 16.65 12 16391 2765 79725220
Blood alkaline phosphatase increased 24.92 16.65 46 16357 63618 79664367
Pain in extremity 24.89 16.65 23 16380 364515 79363470
Blood bilirubin increased 24.86 16.65 47 16356 66185 79661800
Subclavian artery occlusion 24.77 16.65 6 16397 168 79727817
Systemic candida 24.60 16.65 16 16387 6690 79721295
Interstitial lung disease 24.26 16.65 64 16339 112536 79615449
Pseudomonas infection 23.32 16.65 25 16378 20878 79707107
Aspartate aminotransferase increased 23.26 16.65 72 16331 138569 79589416
Pleural effusion 23.05 16.65 74 16329 145188 79582797
Rash erythematous 22.94 16.65 42 16361 57727 79670258
Anaphylactic reaction 22.72 16.65 52 16351 83691 79644294
Pseudomembranous colitis 22.65 16.65 14 16389 5360 79722625
Alanine aminotransferase increased 22.42 16.65 79 16324 162491 79565494
White blood cell count decreased 22.21 16.65 87 16316 188201 79539784
Pain 21.95 16.65 73 16330 703729 79024256
Petechiae 21.90 16.65 24 16379 20541 79707444
Dermatitis exfoliative 21.85 16.65 18 16385 10811 79717174
Neutrophilic dermatosis 21.51 16.65 7 16396 583 79727402
Insomnia 21.25 16.65 12 16391 245158 79482827
International normalised ratio increased 21.23 16.65 51 16352 84670 79643315
Hepatic failure 21.21 16.65 42 16361 61170 79666815
Musculoskeletal stiffness 21.16 16.65 5 16398 175003 79552982
Drug abuse 20.99 16.65 4 16399 162687 79565298
White blood cell count increased 20.97 16.65 47 16356 74586 79653399
Contusion 20.66 16.65 3 16400 148773 79579212
Leukocytosis 20.38 16.65 34 16369 43421 79684564
Uveitis 20.33 16.65 21 16382 16809 79711176
Staphylococcal infection 20.20 16.65 40 16363 58255 79669730
Aplasia pure red cell 20.12 16.65 15 16388 7795 79720190
Antibiotic level above therapeutic 19.95 16.65 7 16396 733 79727252
Drug ineffective 19.72 16.65 136 16267 1080777 78647208
Extravasation blood 19.48 16.65 6 16397 418 79727567
Hepatocellular injury 19.40 16.65 35 16368 47558 79680427
Hepatic function abnormal 19.39 16.65 45 16358 73062 79654923
Sinusitis 19.33 16.65 8 16395 195493 79532492
Blood culture positive 19.11 16.65 15 16388 8414 79719571
Spontaneous haematoma 18.76 16.65 8 16395 1414 79726571
Acanthosis 18.51 16.65 6 16397 493 79727492
Mucosal inflammation 18.40 16.65 45 16358 75535 79652450
Organ failure 18.27 16.65 11 16392 4022 79723963
Depression 18.23 16.65 11 16392 216779 79511206
Swelling 18.22 16.65 11 16392 216700 79511285
Schizophrenia 18.17 16.65 19 16384 15421 79712564
Aspergillus infection 18.08 16.65 21 16382 19140 79708845
Hepatic cytolysis 18.07 16.65 25 16378 27126 79700859
Purpura 17.76 16.65 21 16382 19506 79708479
Bone marrow failure 17.63 16.65 35 16368 51072 79676913
Haemolytic anaemia 17.61 16.65 20 16383 17800 79710185
Muscle spasms 17.52 16.65 7 16396 174723 79553262
Skin oedema 17.21 16.65 8 16395 1733 79726252
Neuralgic amyotrophy 17.20 16.65 5 16398 285 79727700
Bacteraemia 17.19 16.65 27 16376 32797 79695188
Gamma-glutamyltransferase increased 17.15 16.65 36 16367 54644 79673341
Moraxella infection 17.08 16.65 6 16397 631 79727354
Cytomegalovirus infection 16.92 16.65 31 16372 42613 79685372
Clostridium difficile infection 16.90 16.65 31 16372 42654 79685331
Cytarabine syndrome 16.87 16.65 4 16399 102 79727883
Treatment failure 16.81 16.65 7 16396 170479 79557506
SARS-CoV-2 test positive 16.70 16.65 16 16387 11700 79716285
Coagulopathy 16.66 16.65 28 16375 35978 79692007

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CG02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase inhibitors
FDA MoA N0000000202 beta Lactamase Inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D065093 beta-Lactamase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:35625 beta-lactamase inhibitors
FDA EPC N0000175930 beta Lactamase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Abscess of liver indication 27916005
Acute pyelonephritis indication 36689008 DOID:559
Peritonitis indication 48661000
Bacterial pneumonia indication 53084003 DOID:874
Haemophilus influenzae pneumonia indication 70036007
Appendicitis indication 74400008 DOID:8337
Abdominal abscess indication 75100008
Cholecystitis indication 76581006 DOID:1949
Infection due to Staphylococcus aureus indication 406602003
Bacterial cystitis indication 424551004
Nosocomial pneumonia indication 425464007
Ventilator-acquired pneumonia indication 429271009
Sepsis caused by Haemophilus influenzae indication 447685007
Sepsis caused by Serratia indication 449084002
Bacterial pyelonephritis indication 838353009
Staphylococcus Nosocomial Pneumonia indication
Diabetic Foot Infection indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
E. Coli Appendicitis indication
E. Coli Endometritis indication
E. Coli Complicated Appendicitis indication
Inflammatory Disease of Female Pelvic Organs indication
Complicated Skin and Skin Structure Infection indication
E. Coli Peritonitis indication
E. Coli Pelvic Inflammatory Disease indication
Bacteroides Complicated Appendicitis indication
Bacteroides Peritonitis indication
Bacteroides Appendicitis indication
Ecthyma gangrenosum off-label use 17732003
Infection of bone off-label use 111253001
Sepsis of the newborn off-label use 206376005
Diverticulitis of gastrointestinal tract off-label use 271366000
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.19 acidic
pKa2 0.39 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS FOR TREATING BACTERIAL INFECTIONS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS OF TREATING BACTERIAL ILLNESSES
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8685957 Sept. 27, 2032 METHODS OF TREATING BACTERIAL ILLNESSES
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS Dec. 19, 2019 NEW CHEMICAL ENTITY
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS Dec. 19, 2024 GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS April 21, 2025 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-lactamase TEM Enzyme INHIBITOR IC50 6.60 WOMBAT-PK CHEMBL
Beta-lactamase Enzyme IC50 6.29 CHEMBL
Beta-lactamase Enzyme IC50 6.53 WOMBAT-PK
Beta-lactamase Enzyme IC50 7.82 WOMBAT-PK
Beta-lactamase Enzyme IC50 5.47 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 6.65 CHEMBL
Beta-lactamase 1 Enzyme IC50 6.52 DRUG MATRIX
IMI-1; IMI-1 carbapenemase Enzyme IC50 7.52 CHEMBL
Beta-lactamase Enzyme IC50 7.22 CHEMBL
Beta-lactamase Enzyme IC50 6.09 CHEMBL
Beta-lactamase Enzyme IC50 6.72 CHEMBL
Beta-lactamase Enzyme IC50 6.03 CHEMBL
Beta-lactamase Enzyme IC50 7.40 CHEMBL
Beta-lactamase Enzyme IC50 8 CHEMBL
Beta-lactamase Enzyme IC50 8.40 CHEMBL
Carbapenem-hydrolizing beta-lactamase SFC-1 Enzyme IC50 5.16 CHEMBL
Carbepenem-hydrolyzing beta-lactamase KPC Enzyme Ki 4.13 CHEMBL
Beta-lactamase Enzyme IC50 7.02 CHEMBL
Beta-lactamase Enzyme IC50 8.70 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 6.96 CHEMBL
Beta-lactamase Enzyme IC50 6.62 CHEMBL
Beta-lactamase GES-13 Enzyme IC50 7.22 CHEMBL
Beta-lactamase Enzyme IC50 7.10 CHEMBL
Class D beta-lactamase Unclassified IC50 6.80 CHEMBL
Beta-lactamase Enzyme IC50 6.30 CHEMBL
Beta-lactamase Enzyme IC50 8.66 CHEMBL
Beta-lactamase Enzyme IC50 5.70 CHEMBL
Beta-lactamase Enzyme IC50 5.70 CHEMBL
Beta-lactamase Enzyme IC50 7 CHEMBL
Beta-lactamase Enzyme IC50 7.40 CHEMBL

External reference:

IDSource
D00660 KEGG_DRUG
89785-84-2 SECONDARY_CAS_RN
4020843 VANDF
C0075870 UMLSCUI
CHEBI:9421 CHEBI
TAZ PDB_CHEM_ID
CHEMBL404 ChEMBL_ID
DB01606 DRUGBANK_ID
CHEMBL1439 ChEMBL_ID
D000078142 MESH_DESCRIPTOR_UI
123630 PUBCHEM_CID
10789 IUPHAR_LIGAND_ID
6340 INN_ID
SE10G96M8W UNII
221167 RXNORM
30782 MMSL
5543 MMSL
d04404 MMSL
004398 NDDF
004399 NDDF
410931003 SNOMEDCT_US
427652008 SNOMEDCT_US
96007008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 375 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 375 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 375 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9632 INJECTION, SOLUTION 0.25 g INTRAVENOUS NDA 29 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9636 INJECTION, SOLUTION 0.38 g INTRAVENOUS NDA 29 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9638 INJECTION, SOLUTION 0.50 g INTRAVENOUS NDA 29 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections